‘Inertia’ Likely To Restrain Biosimilar Humira In US Market, Experts Say

PBM contracting and payer formulary placement for branded Humira signal headwinds for biosimilar versions in the US, according to participants in an IQVIA-sponsored panel.

Similar
Biosimilars for Humira could experience commercial headwinds in the US

US market dynamics will result in headwinds for drug manufacturers hoping to make a fast return on investment from the sale of biosimilar versions of AbbVie’s blockbuster Humira (adalimumab), industry watchers said during a panel discussion on the US biosimilars market sponsored by the IQVIA Institute on 28 February.

Economic incentives for payers and the pharmacy benefit managers (PBMs) charged with negotiating formulary placement for drugs in the US...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.